XENE

XEN1101 (Potassium Channel Modulator)

Adult Focal Epilepsy

Phase 2 (Top-line Data)

Exp Date

Q3 2021

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: XEN1101 for Adult Focal Epilepsy

  • ClinicalTrial.gov (NCT03796962):A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy


WHAT IS THE CATALYST EVENT?

  • Phase 2 (Top-line Data)


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?


PRIOR DATA/EVENTS

PRESS RELEASE

MECHANISM OF ACTION

  • We are developing XEN1101, a differentiated Kv7 potassium channel modulator, for the treatment of epilepsy and potentially other neurological disorders.

  • The Kv7 potassium channel mechanism has been clinically validated with ezogabine, an earlier generation Kv7 modulator that was approved by the FDA as an adjunctive treatment for adults with focal seizures with or without secondary generalization. XEN1101’s unique composition is chemically designed to improve upon potency, selectivity and pharmacokinetics, or PK, of ezogabine, and is not expected to have ezogabine’s composition-specific tissue pigmentation effects.

MARKET

  • It is estimated that the addressable population in the United States could include approximately 460,000 adults and
    70,000 pediatric patients with focal epilepsy.

Updated by HC

XENE, XEN1101 (Potassium Channel Modulator), Kv7 potassium channel modulator, epilepsy, neurological disorders.

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon